Detalhe da pesquisa
1.
Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and ß2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD).
Bioorg Med Chem Lett
; 41: 127975, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33753262
2.
CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
J Pharmacol Exp Ther
; 352(3): 559-67, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25576075
3.
Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and ß2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases.
J Med Chem
; 65(15): 10233-10250, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35901125
4.
Pharmacological characterization of a highly selective Rho kinase (ROCK) inhibitor and its therapeutic effects in experimental pulmonary hypertension.
Eur J Pharmacol
; 850: 126-134, 2019 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30753868
5.
Acrolein effects in pulmonary cells: relevance to chronic obstructive pulmonary disease.
Ann N Y Acad Sci
; 1259: 39-46, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22758635
6.
Effects of the alpha2-adrenergic/DA2-dopaminergic agonist CHF-1024 in preventing ventricular arrhythmogenesis and myocyte electrical remodeling, in a rat model of pressure-overload cardiac hypertrophy.
J Cardiovasc Pharmacol
; 47(2): 295-302, 2006 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-16495769
7.
Effect of nolomirole on monocrotaline-induced heart failure.
Pharmacol Res
; 49(1): 1-5, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-14597145